STAT

Opinion: Falsehoods and facts about drugs and the people who use them

The issue of drug use is not fundamentally complicated: People will use psychoactive substances, and the first step to more effectively addressing them is to decriminalize their use and possession…
A woman drinks yage in Colombia. Drugs are generally accepted when they are consumed in a traditional manner that a particular culture understands.

A new survey of Americans shows that many regard addiction as a behavioral failing, and most would not welcome those suffering from addiction into their neighborhoods, workplaces, or families. Such attitudes toward addiction, which mirror those in many other countries, perpetuate the abundant false narratives about drugs the world over.

Misrepresentations about drugs fuel stigma and discrimination towards the people who use them. I see this all the time in my work as a member of the Global Commission on Drug Policy. This hinders effective reform and undermines human dignity and the rule of law.

We must find ways to counter prejudice against drug use with facts and break this vicious cycle: drugs are evil and should be illegal → individuals who use them are immoral because drug consumption and possession

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About MorphoSys Drug Risks, An AstraZeneca Admission, And More
MorphoSys is dealing with a safety issue with pelabresib, the experimental treatment for myelofibrosis and centerpiece of its proposed $3 billion acquisition by Novartis.
STAT2 min readCrime & Violence
STAT+: Pharmalittle: We’re Reading About A Medicare Price-negotiation Ruling, Pharma’s Slipping Reputation, And More
A U.S. judge dealt a blow to two drugmakers challenging the authority for Medicare to negotiate the prices of prescription drugs.
STAT2 min readAmerican Government
STAT+: Pharmalittle: We’re Reading About FTC Reviewing Novo-Catalent Deal, Amneal Opioid Settlement, And More
The FTC wants more information on a $16.5 million deal in which Novo Nordisk's parent company would purchase Catalent, a contract drug manufacturer.

Related